Phase 1 PK Study of Cediranib in Single and Multiple Doses in Hepatically Impaired Patients With Solid Tumours

A Phase I, Open Label Study of the Pharmacokinetics and Safety of Cediranib (RECENTINTM, AZD2171) Following Single and Multiple Oral Doses in Patients With Advanced Solid Tumours With Various Degrees of Hepatic Dysfunction

To determine how patients with advanced cancer and various degrees of hepatic impairment will metabolise Cediranib.

Inclusion Criteria:

• Written informed consent
• Advanced solid tumour (not prostate cancer) for which no standard therapy exists
• WHO performance status 0-2
• Bilirubin levels within the target range

Exclusion Criteria:

• Unstable brain/meningeal metastases
• Inadequate bone marrow reserve
• Biochemistry/haematology results outside of required ranges
• History of significant GI impairment